🇺🇸

Broad Market

· daily

US SEC Filings Daily Market Digest — April 01, 2026

Across 50 SEC filings dated April 1, 2026, dominant themes include elevated M&A and SPAC activity (10+ filings: Haymaker, Community West, Cyclerion, Golden Entertainment), mixed financial results with 12 companies showing YoY revenue growth averaging +45% (e.g., Charlie's +169%, RH +8%) offset by sharp declines in 8 firms averaging -38% (Cal-Maine -53%, OLB -32%), and margin expansions in select industrials/biotechs (ASE gross +140 bps to 17.7%) amid compressions elsewhere. Proxy statements (Circle, Weyerhaeuser) highlight positive 2025 recaps and growth strategies, while biotechs/pharmas (Lakewood-Amedex, IceCure, Adaptin) pursue listings/raises amid losses. Capital returns strong in resources (Weyerhaeuser $766M, +5% dividend) and buybacks (News Corp $1B program), but impairments and regulatory risks (LFTD $23M goodwill) pressure consumer/health sectors. Portfolio-level: 60% mixed sentiment, with M&A driving near-term catalysts but cyclical downturns in ag/food/eggs signaling caution. Implications: Favor M&A plays and dividend growers; monitor May shareholder votes for comp approvals/guidance.

33 high priority 17 medium 50 total filings
· daily

Global High-Priority Regulatory Events — April 01, 2026

Across 50 filings on April 1, 2026, critical market events reveal robust M&A and divestiture activity (e.g., CWBC-UBFO merger, CHS hospital sale, Duke Energy asset sale) boosting cash positions and gains, contrasted by liquidity strains in Indian firms via encumbrances (e.g., IndusInd, Embassy) and defaults (Patspin ₹24.37 Cr). Period-over-period trends show polarized performance: revenue growth in semis (ASE +8.4% YoY), foods (ITC Sproutlife +85.2% YoY), but sharp declines in ag/food (Cal-Maine -53% YoY net sales Q1, OLB -32% YoY) and crypto trusts (Osprey net assets -24.4% YoY). SPAC restructurings (Haymaker multiple positives) and biopharma listings (LABT direct listing) signal bullish de-SPAC momentum, while impairments and losses dominate small caps (Amaze -wide net loss, LFTD massive goodwill write-offs). Capital returns strong in timber (Weyerhaeuser $766M), but high debt/encumbrances flag risks; overall sentiment mixed with 14 positive, 16 mixed, 8 negative. Portfolio implications: overweight completed M&A for cash boosts, underweight distressed Indian industrials/banks; watch SPACs and aviation amid geo-risks.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 01, 2026

Across 50 overnight SEC filings (March 31-April 1, 2026), mixed sentiment prevails with 18 mixed, 9 positive, 8 negative, and rest neutral, driven by volatile period-over-period trends: revenue declines averaging -30% YoY in agribusiness (e.g., Cal-Maine -53%, OLB Group -32%) offset by growth in consumer/luxury (RH +8.1%, Charlie's +169%) and select industrials (ASE Tech +8.4%). SPAC/de-SPAC activity surges with 7 filings (Haymaker, Golden Entertainment approvals, Brag House amendments), signaling merger momentum amid $167M+ PIPE raises. Capital allocation leans shareholder-friendly: dividends declared (Weyerhaeuser +5% to $0.21, Cal-Maine $0.36, Global Net Lease $0.19), buybacks (News Corp $1B program, Cal-Maine $24.3M), but cash burn persists in biotechs/small caps. Outliers include RH's net income +72% YoY and Maui Land's leasing +33% YoY, while impairments/goodwill write-offs hit 8 firms (e.g., LFTD $23M). Forward catalysts cluster in April-May (meetings, dividends, acquisitions), implying pre-market volatility in SPACs, foods, and REITs. Portfolio implication: Rotate from cyclical agri declines to SPAC completions and dividend growers for alpha.

31 high priority 19 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 31, 2026

Across 50 8-K filings from March 2026, dominant themes include a surge in M&A transactions (10+ deals like Repay-KUBRA, SCYNEXIS-SCY-770, Red Cat-Quaze), debt refinancings/extensions (Alerus, Prologis, Ares, Lincoln National), and widespread executive changes/appointments (20+ instances, notably Jay Jacobs replacing Shannon Ghia across 8 BlackRock iShares ETF sponsors). Period-over-period trends show revenue growth in standout performers like nCino (+10% FY2026 YoY to $594.8M, first GAAP profit) and T1 Energy (record Q4 production 1.13GW YoY, FY 2.79GW in-line), but persistent losses (T1 Q4 net loss $190M improved from $367M). Forward-looking catalysts cluster in Q2 2026 (merger closings, M&A approvals), with positive guidance in payments/energy/biotech offsetting bankruptcy (Lipella) and wind-downs (Allbirds). Portfolio-level patterns reveal financials/real estate leaning toward neutral refinancing for stability, while biotech/tech exhibit bullish expansion via tuck-ins and equity raises. Capital allocation favors M&A reinvestment over dividends/buybacks, signaling growth conviction amid mixed sentiment (25% positive, 10% negative). Actionable implications: overweight fintech/biotech M&A plays, monitor ETF sponsor stability, avoid distressed pharma.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 31, 2026

Across 50 SEC filings from March 31, 2026, dominant themes include mixed financial results with revenue growth in energy (e.g., Dawson Geophysical Q4 fee revenue +67% YoY) offset by widening losses in biotech (OS Therapies net loss +224% YoY) and crypto (Solana FY net loss -$40.9M widened from -$11.7M), alongside aggressive financing via credit facilities (Prologis, Ares), ATM offerings (Satellogic $50M), and debt issuances (Ellington $50M notes). Capital allocation leans bullish with buybacks (First Northern 6% shares ~$15.6M, Solana $3.4M, News Corp $1B program) and dividends (AGL $0.60/share, SmartStop $0.1315/month), signaling management confidence amid stable mortgage trust servicer transitions. Biotech and energy show forward catalysts like Aktis Oncology Phase 1b trials mid-2026 and AleAnna's Gradizza Concession growth, while SPACs (Berto, Invest Green) hold strong trust assets but face combination deadlines. Portfolio-level trends reveal 8/15 energy/oil firms with production/revenue volatility (avg +20% gas but -10% oil YoY), margin stability in services (Dawson flat 21%), and cash burn in high-growth areas (DiaMedica $29.1M operating cash use). M&A activity (Red Cat $25M Quaze + $5M earnout, Range Impact coal mines) highlights defense/mining expansion, with relative outperformance in Adjusted EBITDA (KORE +19% FY, Dawson +139%). Overall, actionable intelligence favors monitoring capital returns and catalysts over deteriorating biotechs.

33 high priority 17 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 31, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include distress signals in Indian firms (closures, defaults, insolvencies in EID Parry, MT Educare, AGS Transact), mixed US small-cap financials with revenue declines offset by cost controls (e.g., Investview -31% YoY revenue but -12% expenses), and positive M&A/catalyst momentum in biotech/energy (SCYNEXIS acquisition, T1 Energy record production). Period-over-period trends show 8/20 10-K filers with revenue declines averaging -25% YoY (e.g., CKX Lands -45%, HireQuest -11%), but 6/20 improved net losses via impairments/cost cuts; energy outliers like Range Resources +11% sales YoY contrast broader weakness. Capital allocation leans shareholder-friendly in survivors (Marsh $2B buybacks, Range $231M repurchases/$86M dividends), while SPACs/M&A amendments signal delayed but resilient dealmaking (Soulpower $8.5B valuation). RBI amendments tighten acquisition/bridge finance norms, potentially curbing M&A; mortgage trusts highlight routine servicer transitions (Wells Fargo to Trimont March 2025). Portfolio implications: overweight US energy/biotech catalysts, underweight Indian distress names, monitor SPAC closings for Q2/Q3 2026 alpha.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 31, 2026

Across 50 overnight SEC filings, mixed sentiment dominates with 14 mixed, 9 positive, 5 negative, and 22 neutral, reflecting resilient capital allocation amid uneven operational trends; energy firms like AleAnna and Dawson show strong YoY EBITDA growth (AleAnna $6.6M FY, Dawson +139% to $4.7M) offset by renewable losses and flat margins, while biotechs (Aktis, DiaMedica, OS Therapies) report clinical progress but widening net losses (OS +224% to $28.8M). Financials and REITs emphasize shareholder returns via buybacks (First Northern 6% of shares ~$15.6M, News Corp $1B program) and dividends (SmartStop $1.60 annualized, AGL $0.60/share), alongside credit expansions (Prologis global facility, Ares 3-year term loan). M&A activity surges in defense/tech (Red Cat $25M Quaze + Apium acquisitions) and resources (Range Impact coal mines boosting assets 20x to $123M), but SPACs and crypto (Solana $40.9M FY loss despite $325M Q4 net income) highlight volatility. Portfolio-level trends include 7/15 reporting entities with revenue growth >20% YoY (e.g., Dawson Q4 +67%), but 6/12 with margin stability or compression; activist push at Lululemon (8.6% stake, proxy fight) signals governance risks. Key implications: Favor buyback-heavy financials and acquisition-driven small caps pre-market, monitor biotech catalysts into mid-2026.

33 high priority 17 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 30, 2026

Across 50 8-K filings from March 30, 2026, the dominant theme is aggressive capital structure optimization through refinancings, new credit facilities, and note issuances (e.g., Ingevity's $750M revolver, Nexstar's $1.75B Term B-7, MediaAlpha's $150M term/$60M rev), enhancing liquidity without reported performance declines. Strategic M&A and divestitures highlight focus on core operations (Leidos $2.4B ENTRUST acquisition doubling energy exposure; Spire $215M gas marketing sale; Compass $292.5M Sterno divestiture reducing leverage below 1.0x). Biotech sector shows robust funding and milestones (OnKure $150M raise for PI3Kα inhibitors with H1 2027 INDs; Connect Biopharma positive Phase 1 FEV1 improvements ~200-400mL, Phase 2 mid-2026; Aprea $30M for ACESOT-1051 expansion to Q1 2028 runway). Limited period-over-period data reveals mixed guidance (Spire affirms FY2026 $5.25–$5.45 EPS but cuts FY2027 to $5.40–$5.60 from $5.65–$5.85); Inogen reaffirms Q1/FY2026 outlook post positive EBITDA turn. Board changes are prevalent (50% of filings), mostly neutral appointments/resignations, with rare discord (Ensysce director exit over severance). No broad insider trading patterns, but capital allocation leans toward deleveraging and growth reinvestment over dividends/buybacks. Overall, positive sentiment in 40% of filings signals resilience, with opportunities in energy/utilities and biotech amid neutral/mixed financing dilution risks.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 30, 2026

Across 50 SEC filings for March 30, 2026, 10-Ks reveal polarized financial trends with 12/22 reporting revenue growth (avg +85% YoY in winners like General Enterprise Ventures +195%, Embraer +18.5%) but 15 showing widening net losses (avg +150% YoY, e.g., Picard Medical +28%, Origin Materials +198%) amid impairments and high expenses; SPACs (9 filings) universally report no revenue, mounting deficits (avg -$500K), and going concern doubts. Biotech/pharma shines with Alumis' Phase 3 psoriasis trial success and OnKure's $150M raise for PI3K inhibitors, contrasting Dyadic's Nasdaq equity deficiency. Capital allocation favors buybacks (News Corp $1B program, ConocoPhillips $5B in 2025) and financings ($119M Soluna cash surge), while M&A/strategic deals (RYVYL $10M deposit acquisition, Contango exchangeables) signal consolidation. Energy (Conoco, Endeavour) shows resilience with production gains and audit stability, but REITs/CRE (Presidio, CIM) face NOI pressures yet NAV stability. Forward catalysts cluster in H2 2026 (NDAs, pilots) with May 12 AGMs for Conoco/Accelerant; overall, selective bullish signals in biotech/energy amid broad microcap risks, favoring nimble portfolios.

38 high priority 12 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 30, 2026

Across 50 filings from March 30, 2026, focused on global high-priority events, dominant themes include SPAC mergers advancing toward imminent closings, heavy promoter encumbrances and pledge releases in Indian firms signaling liquidity pressures, mixed 10-K results with revenue surges (e.g., OneMedNet +111% YoY) offset by widening losses and impairments (e.g., Origin Materials -40% revenue, $196M impairment), and biotech financings amid going concern warnings. Period-over-period trends reveal 8/15 10-K filers with revenue growth averaging +85% YoY but losses expanding in 10/15 (avg +150%), driven by expense spikes and asset write-downs, while capital raises ($150M OnKure, $750M Ingevity revolver) bolster balance sheets. Critical developments like Vine Hill's 92.6% merger approval (closing Mar 31), IL&FS bond default, and IndusInd SFIO probe heighten volatility risks. Portfolio-level patterns show crypto/AI names with asset growth but volatility (AIxCrypto assets +568% YoY), shipping/energy facing covenant pressures, and Indian banks/pharma with encumbrance fluctuations (e.g., IndusInd promoters to 0% encumbered). Implications favor short-term trading around catalysts like Mar 31 closings and May AGMs, with caution on insolvencies and Nasdaq deficiencies.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 30, 2026

Across 50 overnight SEC filings, dominant themes include mixed financial results in 10-Ks with revenue growth in 6/15 reporting companies (avg +60% YoY outliers like General Enterprise Ventures +195%) offset by widening losses (e.g., Picard Medical net loss +28%, Origin Materials -198%) and impairments; SPACs (8 filings) universally show no revenue, cash burn, and going concern doubts. Biotech sector shines with positive trial data (Alumis Phase 3 success) and funding ($150M OnKure), while energy (ConocoPhillips +15% drilling efficiency) and aviation (Embraer +18.5% revenue) report strength amid margin pressures. Capital allocation leans toward buybacks (News Corp $1B program) and dividends (steady in Presidio, Cottonwood), but debt issuances/amendments (Amphenol, Nexstar $1.75B) signal leverage. Forward-looking catalysts cluster in H2 2026 (NDAs, pilots, data readouts), with M&A momentum (RYVYL, Volato). Portfolio-level: Margin compression avg -50bps in 7/10-Ks, cash surges via financing in 5 firms (Soluna +$68M), but Nasdaq deficiencies and going concerns flag 4 high-risk names. Implications: Tactical buys in biotech/energy catalysts, caution on microcaps/SPACs pre-market.

38 high priority 12 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 27, 2026

Across the 50 US SEC filings from March 27, 2026, the dominant themes are widespread executive and board transitions (observed in 25+ filings, including 10+ CEO/CFO changes and 15+ director resignations/appointments), robust financing and refinancing activities (16 instances, including $1.5B+ facilities and $500M+ debt/equity raises), and select M&A/spin-off developments amid neutral-to-positive sentiment (avg materiality 7/10). No explicit aggregate YoY/QoQ financial trends are detailed, but implied liquidity enhancements via new credit lines (e.g., Delek, Enterprise, News Corp) and equity facilities (Cyber Enviro-Tech $30M, LM Funding $75M) signal proactive capital allocation for growth/reinvestment over dividends/buybacks. Critical developments include AnaptysBio's value-unlocking spin-off (April 20 distribution), Two Harbors' $10.80/share merger (H2 2026 close), and Iterum Therapeutics' liquidation petition (hearing April 13)—flagging biotech distress vs. sector resilience. Portfolio-level patterns show shipping/energy firms focusing on debt refinancing (positive for stability), SPACs/biotechs with leadership churn (mixed conviction), and cruise/retail with activist-driven board refreshes (Norwegian Cruise). Market implications: heightened M&A catalysts, monitor leadership stability for conviction signals, and favor liquidity-strong names amid potential volatility from transitions.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 27, 2026

The March 27, 2026, SEC filings digest reveals a dominant proxy season theme with 15+ DEFA14A/DEF 14A filings for May 2026 AGMs across sectors like airlines (Southwest, Murphy Oil), pharma (Indivior, Nurix), and metals (Trilogy), signaling routine governance but highlighting positive 2025 recaps (e.g., Indivior revenue +4% YoY to $1.24B, Murphy Oil production +3% YoY to 182 MBOEPD). 10-Ks show stark mixed performance: revenue growth in Sportradar (+17% YoY to €1.29B), BitGo (+424% to $16.2B), but declines in Luminar (-12% YoY to $66M), Phunware (-20% YoY to $2.6M), and SpringBig (-7% YoY to $22.8M), with margin expansions in Indivior (+500 bps to 35%) offset by compressions elsewhere. Biotech shines with Kodiak's Phase 3 GLOW2 success and Nurix's 83% ORR, while credit funds (Oaktree, Blue Owl) maintain stable leverage (0.57x-0.82x) and distributions ($0.0748/share monthly). SPACs/blank checks (BHAV, AltEnergy) report IPOs and leadership changes, and capital allocation favors returns (Indivior $400M buyback, News Corp $1B repurchase). Overall, portfolio trends indicate resilient credit/income strategies amid tech/autonomy weakness, with May AGMs as key catalysts for comp votes and auditor ratifications.

28 high priority 22 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 27, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include M&A activity (e.g., mergers, spin-offs, amalgamations), regulatory non-compliances and penalties (prevalent in Indian firms), distress signals like debt defaults, delisting risks, and going concern doubts in biotechs, alongside positive credit facilities and IPOs/SPACs. Period-over-period trends show mixed revenue performance: standout growth in Alamar Biosciences (+195% YoY to $74.2M), Sportradar (+17% to €1,290M), Equifax (+7% to $6.075B), and Indivior (+4% to $1.24B), but sharp declines in Origin Materials (-40% FY2025 to $18.9M) and Sarda Proteins (revenue to 57,627 Lakhs from 97,596 Lakhs). Biotech sector exhibits bifurcation with AnaptysBio spin-off ($180M cash runway) contrasting VivoSim and BiomX distress; financials see refinancing positives (Enterprise $1.5B facility, Delek new credit agreement). Critical implications: heightened insolvency risks in infrastructure/Indian firms (IL&FS default, Shirpur/Setubandhan CIRP), M&A catalysts for value unlock (Two Harbors $10.80/share takeover, Bank of Nagoya integration), and proxy-driven governance shifts (Norwegian Cruise board refresh). Portfolio-level patterns flag Indian regulatory fines averaging ~₹5-12L across 5+ firms, biotech cash runways extending to 2027 with dilution risks, and energy/REITs prioritizing capital returns amid stable metrics.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 27, 2026

Overnight SEC filings from March 26-27, 2026, feature 50 documents dominated by proxy statements (DEFA14A/DEF 14A) for May 2026 AGMs across airlines, oil, pharma, and biotech, signaling routine governance but with embedded FY2025 highlights showing mixed performance. Period-over-period trends reveal revenue growth in 8/15 10-Ks (e.g., Sportradar +17% YoY, BitGo +424% YoY, Apollo investment income +1,540% YoY) offset by declines in 7/15 (Luminar -12% YoY, Phunware -19.9% YoY, SpringBig -7.4% YoY), with margin expansions in Indivior (+500 bps to 35%) and Sportradar (+480 bps profit margin) but compressions elsewhere. Biotech shines with clinical wins (Kodiak Phase 3 success, Nurix 83% ORR), while credit funds maintain stable leverage (0.57x-0.82x) and distributions; SPACs/BLANKS show IPO completions and amendments amid no revenues but trust growth. Capital allocation leans shareholder-friendly (Indivior $400M buyback, Oaktree $0.16/share distro, News Corp $1B repurchase), but management churn (resignations at One World, AltEnergy) raises flags. Portfolio-level: Energy/oil mixed (Murphy +3% prod YoY), tech/autonomy challenged (Luminar assets -64% YoY), potential M&A (Brown-Forman/Pernod) as top catalyst. Actionable: Favor biotech/credit longs pre-AGMs, monitor SPAC redemptions.

28 high priority 22 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 26, 2026

Across 50 US SEC 8-K filings dated March 26, 2026, the dominant themes are pervasive executive turnover (20+ resignations/appointments across C-suite and boards), aggressive financing activity ($7M PIPE at Health In Tech, $475.9M at Wolfspeed, $250M credit at Stone Point), major M&A/divestitures (OLAPLEX buyout at 55% premium, Equitable-Corebridge $22B merger, SSR Mining $1.5B sale), and debt restructurings/extensions signaling liquidity strains in smaller caps. Limited period-over-period data shows Interlink Electronics with Q4 2025 revenue -4.5% YoY to $2.853M, gross margins -790 bps to 31.7%, but FY revenue +1.8% to $11.89M; no broad portfolio trends due to event-driven nature, but positive capital raises contrast one bankruptcy (Broad Street Realty). Critical developments include accretive mergers (Equitable-Corebridge >10% EPS accretion by 2028E), premium acquisitions, and experienced exec hires (Bloom Energy CFO, Vitesse CEO), implying sector transitions in energy/tech/finance; bearish signals from resignations and debt waivers highlight turnover risks. Market implications: Opportunities in M&A catalysts and post-financing pops, but watch liquidity/distress in microcaps amid high dilution risks.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 26, 2026

Across 50 SEC filings for March 26, 2026, FY2025 results dominate with mixed outcomes: 14/22 10-Ks showed revenue growth averaging +15% YoY (e.g., Lumexa +7.8%, TXO +41.8%, Leef Brands +22.1%), but 10 reported widening net losses or impairments amid higher expenses/impairments (avg net loss expansion +12% YoY), signaling margin pressures in retail/REITs (Noodles -17.5% net loss YoY). SPAC/de-SPAC and M&A activity surges (12 filings, e.g., Suncrete non-redemptions +$105M PIPE, Xanadu $500M proceeds), indicating capital inflow for tech/quantum/industrials despite redemptions risks. Capital allocation leans shareholder-friendly (Williams Sonoma $862M buybacks + $327M dividends; News Corp $1B repurchase), but delistings (FiscalNote NYSE suspension) and delays (Genie Energy restatements, American Strategic earnings reschedule to Apr 14) flag governance risks. Healthcare outliers: Lumexa bullish (EBITDA +14.6% YoY, 2026 guidance $1.045-1.097B rev) vs Strata Skin rev -9% YoY. Energy mixed (TXO rev +42% but impairments; Canadian Nat reserves +4.5%). Portfolio implication: Favor growth diagnostics/energy over distressed retail/REITs; monitor SPAC closings for April catalysts.

35 high priority 15 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 26, 2026

Across 50 US SEC filings dated March 26, 2026, focused on global high-priority events, a mixed sentiment prevails with 18 mixed, 8 positive, 7 neutral, and 3 negative, highlighting financial distress (1 bankruptcy, multiple debt restructurings/amendments) juxtaposed against opportunistic financings and narrowing losses in biotechs/small caps. Period-over-period trends show revenue divergence: 12/25 quantifiable 10-K/10-Qs reported YoY declines averaging -7.5% (e.g., Lands' End -2%, NORTECH -7.6%, VirTra -15%), while 13 showed growth averaging +72% (e.g., AmpliTech +165%, Nyxoah +122%, Spero +39%), with margins expanding in 8/15 cases (avg +210 bps, e.g., Lands' End +80 bps, NORTECH +210 bps). Biotech/pharma cluster (10 filings) averaged net loss narrowing 25% YoY amid R&D cuts, but cash burns persisted; retail/apparel saw uniform sales drops (-2% to -5.6%). Capital allocation leans defensive (dividend hikes in Shoe Carnival +11%, Lands' End implied stability; Newmont $3B buybacks), with forward catalysts clustering in May 2026 proxy votes (15+ meetings) and debt/acquisition milestones (Keurig JDE Peet's by Feb 2027). Critical implications: imminent liquidation risks (Broad Street Realty), dilution threats (Sadbhav MRA equity conversions, Wytec warrants), but alpha in turnaround plays (Spero swung to profit) and growth outliers (Paychex +19.8% revenue). Portfolio pattern: monitor small-cap distress vs. large-cap stability for relative outperformance.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 26, 2026

Across 50 overnight SEC filings for March 25-26, 2026, FY2025 results dominate with mixed outcomes: 12/20 major 10-Ks showed revenue growth averaging +12% YoY (e.g., Lumexa +7.8%, Leef Brands +22.1%, TXO Partners +41.8%), but net losses widened in 8/20 cases amid impairments, higher expenses, and debt costs; REITs and BDCs exhibited portfolio stress with yields declining (BlackRock Multifamily 4.5%, AB Private Credit 9.58% vs 10.51%). SPAC/de-SPAC momentum is strong with 8 filings advancing mergers (Suncrete non-redemptions, Enhanced Games IPO path, Xanadu $500M proceeds), signaling M&A alpha in tech/AI/quantum. Capital allocation leans defensive: buybacks (Williams Sonoma $862M, News Corp $1B program), dividends stable, but leverage rose in energy (TXO +85%). Healthcare/imaging outperforms (Lumexa advanced procedures +14.2% Q4 YoY, leverage down to 3.5x), while banks face NIM expansion offset by provisions (United Security ROA - to 1.01%). Delistings (FiscalNote) and restatements (Genie Energy) flag risks; forward catalysts cluster in Q2 (proxies, earnings April-May). Overall, selective bullishness in growth niches amid broad profitability pressure, favoring de-SPACs and reiterated guidance plays pre-open.

35 high priority 15 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 25, 2026

Across 50 SEC 8-K filings from March 25, 2026, dominant themes include widespread board and executive transitions (24 instances of appointments, resignations, retirements across firms like Brand Engagement, Ingredion, HBT Financial, Comstock, Conduent, etc.), signaling proactive governance refreshes amid strategic pivots; robust debt management with 8 credit amendments/extensions (Cipher Mining, Synergy CHC, Senior Credit, Waste Management, Albemarle) enhancing liquidity; active M&A and asset transactions (Sandisk $1B Nanya stake, Fresh Del Monte $285M acquisition, Terns $6.7B Merck buyout, Hecla $160M mine sale); and financings (Apogee $377M equity, Blue Water $125M SPAC IPO, Ballston Spa $26M notes). Period-over-period trends are sparse but notable: Maze Therapeutics cash runway extended 83% YoY to $360M (runway to 2028) despite net loss widening to $131.1M from $52.2M profit (R&D +30% YoY, G&A +31%); CIMG Q1 FY2026 revenue exploded to $15.8M from $23k YoY (+69,000%); Generac FY2025 sales $4.2B with Residential EBITDA $558M. Positive sentiment prevails (28/50 filings), especially biotech/pharma (Maze Phase 2 success, Terns M&A) and energy/mining deleveraging; portfolio implications favor monitoring biotech catalysts and governance-improved names for alpha, while watching leadership vacuums and mixed financials like Maze/CIMG delisting risks.

50 high priority 50 total filings